Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
NSCLC (Non-small Cell Lung Cancer): early-phase trial registry
10 of 11 indexed NSCLC (Non-small Cell Lung Cancer) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,577 of 28,707 conditions by registered trial count.
11 US clinical trials · 10 currently recruiting · #1,577 of 28,707 conditions by registered trial count
NSCLC (Non-small Cell Lung Cancer): 11 US clinical trials tracked, 10 recruiting.
NSCLC (Non-small Cell Lung Cancer) is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 10 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is Indaptus Therapeutics, running 1 of these trials.
Enrollment posture brief
Registry condition nsclc-non-small-cell-lung-cancer
OPEN 10 | RECR 91% | LATE 1 | EARLY 8 | RANK #1577 | SPON 1
Volume-matched condition peers
Nearest open-share peer: CRC, Colorectal Cancer (91% recruiting · 11 trials)
NSCLC (Non-small Cell Lung Cancer) lists 10 open slots (91% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for NSCLC (Non-small Cell Lung Cancer) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
NSCLC (Non-small Cell Lung Cancer) is recruiting above its size-band peers.
10 of 11 indexed trials (90.9%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of NSCLC (Non-small Cell Lung Cancer) trials is spread across many organizations.
Indaptus Therapeutics accounts for 1 of 11 trials (9.1%). 11 distinct sponsors appear on at least one study for this condition label.
-
Typical NSCLC (Non-small Cell Lung Cancer) enrolment sits around 200 participants.
Median target enrolment is 200 among the 11 trials that report a genuine target (sentinel values excluded). 1 of those (9.1%) plan for fewer than 100 participants.
-
NSCLC (Non-small Cell Lung Cancer) research is mostly interventional.
9 interventional and 2 observational studies make up this index (81.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
11 total, page 1 of 1
Pan-tumor MRD Study
Paradigm Health
NCT06605404
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Revolution Medicines
NCT06881784
Study of XB010 in Subjects With Solid Tumors
Exelixis
NCT06545331
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Iambic Therapeutics
NCT06253871
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
A2 Biotherapeutics
NCT06682793
Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform
Elephas
NCT05478538
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Alterome Therapeutics
NCT06835569
A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946
Yuhan Corporation
NCT06616766
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Nuvectis Pharma
NCT05873686
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Radiopharm Theranostics
NCT07189871
Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors
Indaptus Therapeutics
NCT05651022
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on NSCLC (Non-small Cell Lung Cancer) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on NSCLC (Non-small Cell Lung Cancer) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this NSCLC (Non-small Cell Lung Cancer) page
11 registered trials, 10 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 10 NSCLC (Non-small Cell Lung Cancer) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Indaptus Therapeutics sponsors the most NSCLC (Non-small Cell Lung Cancer) trials on record, review their full trial history before evaluating a specific study. See Indaptus Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This NSCLC (Non-small Cell Lung Cancer) condition card totals 11 registered trials; most-linked intervention Decoy20; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.